Inflammatory bowel disease (IBD) is a multifactorial disease involving the interaction of the gut microbiota, genes, host immunity, and environmental factors. Dysbiosis in IBD is associated with pathobiont proliferation, so targeted antibiotic therapy is a rational strategy. When restoring the microbiota with probiotics, it is necessary to take into account the mutual influence of co-cultivated microorganisms, as the microbiota is a dynamic community of species that mediates homeostasis and physiological processes in the intestine. The aim of our study was to investigate the recovery efficacy of two potential probiotic bacteria, L. johnsonii and E. faecalis, in Muc2−/− mice with impaired mucosal layer. Two approaches were used to determine the efficacy of probiotic supplementation in mice with dysbiosis caused by mucin-2 deficiency: bacterial seeding on selective media and real-time PCR analysis. The recovery time and the type of probiotic bacteria relocated affected only the number of E. faecalis. A significant positive correlation was found between colony-forming unit (CFU) and the amount of E. faecalis DNA in the group that was replanted with probiotic E. faecalis. As for L. johnsonii, it could be restored to its original level even without any additional bacteria supplementation after two weeks. Interestingly, the treatment of mice with L. johnsonii caused a decrease in the amount of E. faecalis. Furthermore, either L. johnsonii or E. faecalis treatment eliminated protozoan overgrowth caused by antibiotic administration.
Gastrointestinal diseases in calves remain a serious challenge in livestock production, necessitating the search for effective alternatives to antibiotic therapy. This study compared two formulations of the probiotic Bacillus subtilis—a liquid suspension and a hydrogel tablet based on monophosphorylated starch—in terms of fecal recovery, clinical efficacy, and effects on the composition of the culturable microbiota. A kanamycin-resistant strain of B. subtilis was used to prepare both formulations. The starch carrier was chemically modified by monophosphorylation to confer protective and pH-responsive properties. The release kinetics of bacteria from the tablets were evaluated in vitro using sequential buffer solutions simulating the gastrointestinal tract of calves (pH 6.0, 2.2, and 7.6). The in vivo experiment was conducted on 20 calves with diarrhea, divided into control, suspension, and hydrogel groups. Fecal consistency was assessed using a 4-point scale, bacterial titers were determined by plate counting, and Candida spp. DNA content was quantified by real-time PCR. The hydrogel formulation provided prolonged bacterial detection in feces: by day 14, the titer in the suspension group had significantly decreased, whereas viable cells in the hydrogel group were maintained at a significantly higher level (p = 0.023). Both probiotic formulations contributed to the normalization of fecal consistency by day 3 after treatment withdrawal (p = 0.013 for the suspension and p = 0.005 for the hydrogel), while no improvement was observed in the control group (p = 0.057). Candida spp. DNA levels significantly decreased in the treated groups by days 3 and 14 (p < 0.001), indicating suppression of fungi by B. subtilis. The in vitro modeling confirmed the protective properties of the starch matrix, with only minimal reduction in bacterial titer at pH 2.2. Thus, the hydrogel formulation based on monophosphorylated starch ensures prolonged retention of B. subtilis in the intestine, enhances the therapeutic effect against diarrhea, and contributes to the reduction in Candida spp. in feces. These findings support the potential of this formulation as a promising probiotic delivery system for veterinary practice.